Arkadios Wealth Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Arkadios Wealth Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18K	Hold	20,000	–	–	﹤0.01%	1673
2025 Q4	$15.5K	Hold	20,000	–	–	﹤0.01%	1551
2025 Q3	$24.8K	Hold	20,000	–	–	﹤0.01%	1453
2025 Q2	$31.8K	Buy	20,000 +10,000	+100%	+$9.16K	﹤0.01%	1299
2025 Q1	$14.9K	Hold	10,000	–	–	﹤0.01%	1117
2024 Q4	$40K	Buy	10,000 +2,000	+25%	+$13.5K	﹤0.01%	908
2024 Q3	$100K	Buy	8,000 +2,000	+33%	+$33.7K	0.01%	876
2024 Q2	$87.6K	Buy	6,000 +2,000	+50%	+$35.8K	0.01%	803
2024 Q1	$89.7K	Hold	4,000	–	–	0.01%	678
2023 Q4	$75.7K	Hold	4,000	–	–	0.01%	679
2023 Q3	$68.4K	Buy	+4,000	New	+$95.1K	0.01%	652

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Arkadios Wealth Advisors's CTXR Position: Q1 2026 in Review

Arkadios Wealth Advisors held its Citius Pharmaceuticals (CTXR) position steady in Q1 2026 at 20,000 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #1673.

Arkadios Wealth Advisors first reported a position in CTXR in Q3 2023 and has held it in 11 quarters since. The position peaked at $100K in Q3 2024. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

Arkadios Wealth Advisors held 20,000 shares of Citius Pharmaceuticals worth $18K as of Q1 2026.
Arkadios Wealth Advisors left its Citius Pharmaceuticals share count unchanged in Q1 2026.
Citius Pharmaceuticals made up ﹤0.01% of Arkadios Wealth Advisors's portfolio in Q1 2026, its #1673 holding.
Arkadios Wealth Advisors first reported a position in Citius Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Arkadios Wealth Advisors's Citius Pharmaceuticals position peaked at $100K in Q3 2024.
38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.